A typical course of treatment with Kyprolis lasting, say, five months, can cost around$50,000.
使用Kyprolis治疗一个疗程,也就是5个月,花费大约5万美元。
Little surprise, then, that big drugmakers are keen to develop their own cancer drugs, formpartnerships with smaller firms that have promising treatments in the pipeline, and buysuch companies outright.
有个小惊喜就是大制药公司都热衷于开发自己的抗癌药物,与在治疗过程中能提高治疗效果的小公司形成合作关系,也直接收购这种小公司。
Kyprolis was first developed by a small firm called Proteolix, which was bought by Onyx, nowacquired by Amgen.
首先Kyprolis是由一个叫 Proteolix的小公司开发的,被Onyx收购,现在又被Amgen收购。
In 2009 Bristol-Myers Squibb, an American drug giant, paid $2.4 billion for Medarex, whichhad an experimental immunotherapy drug.
美国制药业巨头施贵宝,2009年斥资24亿美元收购了拥有免疫治疗药物的Medarex公司。
That drug, for melanoma, is now sold in America for $120,000 for a full course of treatment.
该药物对黑色素瘤,现在在美国一个完整的疗程需要12万美元。
There are risks, however.
风险还是有的。
【2015考研英语阅读医药公司和癌症】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30